Cullinan Therapeutics Inc. Common Stock (CGEM)

About CGEM

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecifi…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

109

Website

cullinantherapeutics.com

Fundamentals

1-day range

$18.61$20.37

Market cap

$998.69M

P/E (trailing)

—

P/E (forward)

-7.47

EPS (trailing)

$-3.11

Dividend yield

—

Beta

-0.02

Avg. volume

989.4K

Forecasts

11 analyst ratings

Cullinan Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CGEM

  Cullinan Therapeutics Inc. Common Stock

  $21.72

  ▼ 3.89%
  Market cap $998.69MP/E —
  $5.68$21
• MGTX

  MeiraGTx Holdings plc Ordinary Shares

  $13.8

  ▼ 2.40%
  Market cap $1.10BP/E 15.54
  $6.62$15.35
• SANA

  Sana Biotechnology Inc. Common Stock

  $3.93

  ▼ 3.91%
  Market cap $884.97MP/E —
  $2.61$6.55
• VOR

  Vor Biopharma Inc. Common Stock

  $22.66

  ▼ 3.70%
  Market cap $1.16BP/E —
  $6.5$49.95
• SLDB

  Solid Biosciences Inc. Common Stock

  $9.78

  ▼ 3.46%
  Market cap $789.57MP/E —
  $3.79$11.45
• IMTX

  Immatics N.V. Ordinary Shares

  $9.45

  ▲ 0.91%
  Market cap $1.21BP/E —
  $5.05$12.41
• INBX

  Inhibrx Biosciences Inc. Common Stock

  $123.93

  ▼ 0.00%
  Market cap $1.21BP/E —
  $26.19$155.29

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
  Benzinga · 8/13/2026
• Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42
  Benzinga · 8/13/2026
• 12 Health Care Stocks Moving In Thursday's Pre-Market Session
  Benzinga · 8/13/2026
• Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones
  ChartMill · 8/6/2026
• Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate
  Benzinga · 8/6/2026

• Jennifer Michaelson · July 6, 2026 · Option Exercise

  4.0K @ $4.3
• Jennifer Michaelson · July 6, 2026 · Sale

  8.0K @ $17.82
• Jacquelyn L. Sumer · June 30, 2026 · Grant

  2.5K @ $8.6
• Mary Kay Fenton · June 30, 2026 · Grant

  1.5K @ $8.6
• Meek David D. · June 16, 2026 · Grant

  25.3K
• Rosenberg Anthony · June 16, 2026 · Grant

  25.3K
• Webster Stephen W · June 16, 2026 · Grant

  25.3K
• Allen Andrew R · June 16, 2026 · Grant

  21.8K
• Thistle Mary · June 16, 2026 · Grant

  25.3K
• Jennifer Michaelson · May 5, 2026 · Option Exercise

  4.0K @ $4.3
• Jennifer Michaelson · May 5, 2026 · Sale

  200 @ $15.58
• Jennifer Michaelson · May 5, 2026 · Sale

  7.8K @ $14.6
• Jennifer Michaelson · March 5, 2026 · Option Exercise

  4.0K @ $4.3
• Jennifer Michaelson · March 5, 2026 · Sale

  8.0K @ $15.68

Institutional Ownership

March 31, 2026

Total shares held

64.57M

Total value held

$885.47M

Institutional holders

167